Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder Tumor Resection

TCC Clinical Trial

Official title:
Perioperative Intravesical Instilation of Hypertonic Saline Following Bladder

Status Active, not recruiting

Clinical Trial Summary

Hypertonic saline at the concentration of 3% (hypersel) has been injected for years into echinococcal cysts to kill live scolices, and is also known to kill suspended cells by means of a steep osmotic gradient and the investigators postulate that perioperative intravesical instillation of hypersel for patients with low grade bladder cancer is safe and may be active against shedded and suspended tumor cells and thus may decrease recurrence risk.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04147182
Study type	Interventional
Source	Kaplan Medical Center
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	December 2, 2018
Completion date	November 3, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT04671407` - The Aim of This Study is to Compare the Efficacy of Perioperative Hypertonic Saline 3% Versus Normal Saline (0.9%) in Decreasing Recurrence Risk in Non-muscle Invasive Bladder Cancer	Phase 2